Share ownership Tibet Duo Rui Pharmaceutical Co., Ltd.

301075

CNE100004RW5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 2026-09-30			5-day change	1st Jan Change
63.17 ^CNY	-1.33%		-4.55%	+5.87%

09-28	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
09-20	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI

Share class: Tibet Duo Rui Pharmaceutical Co., Ltd.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	80,000,000	23,595,383 ( 29.49 %)	0	29.49 %

Major shareholders: Tibet Duo Rui Pharmaceutical Co., Ltd.

Name	Stocks	%	Valuation
China Asset Management Co., Ltd. 0.0394 %	10,800	0.0394 %	92 895 ¥
Orient Fund Management Co., Ltd. 0.0263 %	7,200	0.0263 %	61 930 ¥
Hongde Fund Management Co., Ltd. 0.005834 %	1,600	0.005834 %	13 762 ¥
CCB Principal Asset Management Co., Ltd. 0.001094 %	300	0.001094 %	2 580 ¥
Cinda Fund Management Co. Ltd. 0.000729 %	200	0.000729 %	1 720 ¥
Penghua Fund Management Co., Ltd. 0.000729 %	200	0.000729 %	1 720 ¥
Zhong Ou Asset Management Co., Ltd 0.000365 %	100	0.000365 %	860 ¥

Breakdown by shareholder type

Institutional	0.07%
Unknown	99.93%

Based on 1000 largest holdings

Geographical origin of shareholders

China

0.07%

Based on 1000 largest holdings

Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

Calendar

10-29 Earnings release - Q3 2026

More about the company